Vaxil Bio Ltd V.VXL

Alternate Symbol(s): VXLLF

Healthcare Biotechnology

Vaxil Bio Ltd. is a Canada-based biotechnology company. The Company is focused on a drug discovery and development platform based on Signal Peptides (SPs) which the Company deploys to fight infectious diseases and cancer. The Company’s most advanced product, ImMucin, a MUC1 SP-derived vaccine, completed a Phase I/II clinical trial in multiple myeloma. The Company also has a SP-based COVID-19 vaccine candidate and a SP-based tuberculosis vaccine / treatment candidate. In addition, The Company has mAb candidates for the treatment of oncology and infectious diseases to be used alone, and in combination with other treatments. It has also initiated a pre-clinical program for a drug delivery polymer that targets high affinity E-selectin (P-Esbp), which the Company licensed for development and commercialization from BGN Technologies. It exploits the properties of SP domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens.

TSXV:VXL - Post by User

Vaxil Bio Ltd

Bullboard Posts

Post by Thesmartway1111on Mar 12, 2020 8:18pm

154 Views

Post# 30801964

3 US stocks similar

shares of Inovio Pharmaceuticals (NASDAQ:INO), Novavax (NASDAQ:NVAX), and Co-Diagnostics (NASDAQ:CODX) went soaring skyward during the week ended Feb. 28. All three of these biotechs are developing tests and vaccines that could eventually be used to protect billions of people from potentially fatal COVID-19 infections.

Bullboard Posts

The top TSX healthcare stocks under $1